Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Go Back

Share this story

Comments


Related articles


Adam Ellenstein and Susan Scarlett lead

Interviews

Setting a Guinness World Record for Parkinson’s was the proudest moment of my life

105km swim for Parkinson’s verified as new Guinness World Record

READ MORE
fighting Parkinson's

Interviews

“I’m just fighting my corner”

The latest in our monthly series profiling WPC2019 bloggers

READ MORE

Women and Parkinson's

Women and Parkinson’s: menstruation, medication and motherhood

Our podcast shines a light on how women experience the condition

READ MORE